CGI Partners with ICON's Laboratory Services for Comprehensive Oncology Laboratory Testing and Solutions
Corporate Updates

CGI Partners with ICON’s Laboratory Services for Comprehensive Oncology Laboratory Testing and Solutions

Views: 782
Representational image

Representational image

Cancer Genetics, Inc. and ICON have entered into an agreement to offer biotech and pharmaceutical clients access to ICON Laboratory Services, combined with Cancer Genetic’s expertise in oncology testing and genomic assay development.
The partnership will provide clients access to combined expertise ranging from complex, oncology-focused genomic testing to core central laboratory analysis, project and data management and sample logistics on a global basis.
Oncology testing services are the core focus area for both CGI and ICON Laboratory Services. Together, the two companies will leverage their respective expertise to provide key insights to the oncology drug development and clinical trial process. The partnership is focused on providing a comprehensive, integrated and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV.
“We are looking forward to working with the CGI team and to enhancing our client offering with complementary laboratory service programs,†said James Miskel, Executive Vice President, ICON Laboratory Services.  “Together, CGI and ICON are uniquely positioned to provide a full range of comprehensive lab solutions for our customers with current and future oncology-focused clinical trials.â€
With the projected value of the cancer diagnostics market estimated to reach US$169B globally by 2020, the industry has growing demand for complex oncology laboratory testing services. CGI provides complex genomic testing for six out of ten major pharmaceutical companies in the US.
“This partnership will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating CGI’s specialised, genomic testing to ICON’s laboratory solutions, “said Panna Sharma, CEO of Cancer Genetics.â€

Recommended from all portals

Latest News

To Top